The assay predicts both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
PreludeDx and Quanterix Corp highlighted that AidaBREAST, a multi-omic assay to predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer, was developed on Akoya PhenoImager HT platform using Opal chemistry.
It marks a milestone in the clinical application of spatial proteomics by combining spatial multiplex protein expression with targeted next-generation ribonucleic acid (RNA) sequencing for a detailed assessment of tumor biology, according to a release from the company.
The validation of the test included 922 hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) invasive breast cancer patients across four academic and clinical centers in the US and Sweden. With a median follow-up of approximately 10 years, the study demonstrated the test is prognostic for 10-year locoregional recurrence risk and predictive for radiation therapy benefit. According to the companies, these two capabilities were not previously available to clinicians in a single assay for early-stage invasive breast cancer.
[Related: Ataraxis AI Launches Test to Predict Response to Neoadjuvant Therapy in Breast Cancer]
“AidaBREAST harnesses the power of spatial biology and AI to provide unique insights into the tumor and immune-microenvironment not available from clinicopathology,” says Karuna Mittal, PhD, senior director of research and development at PreludeDx and co-author of the study, in a release. “For the first time, oncologists have a tool that tells them not just how likely a patient is to recur, but whether radiation therapy is actually going to help that specific patient. That is a meaningful shift in how we can better inform treatment decisions.”
The platform uses spatial multiplex protein expression, targeted next-generation sequencing, and artificial intelligence to provide insights into the tumor microenvironment.
[Related: DNA Barcode Tech Maps Complex Protein Interactions for Cancer Diagnostics]
“AidaBREAST is exactly the kind of scientific achievement that demonstrates what is possible when spatial proteomics is applied with rigor and clinical intent,” says Everett Cunningham, chief executive officer of Quanterix, in a release. “PreludeDx’s ability to develop a truly novel tool on our PhenoImager HT platform – that also performs reliably and reproducibly across multiple institutions and years of archived tissue, speaks to the immediate opportunity for spatial proteomics in clinical oncology.”
Findings from the study were presented by Dr Karuna Mittal at the American Association for Cancer Research (AACR) Annual Meeting 2026 on April 21.
ID 2122395 © Olivier Le Queinec | Dreamstime.com
